Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market capUnder $500B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Friday, October 23, 2026· 10059 stock ideas· 219 writers·
23,493 views· 11,161 clicks

From X

@marginofdanger 1 click

marginofdanger on X

Ackman's closed end fund $PSUS will begin trading on Wednesday. For every 5 shares of PSUS, IPO investors (only) will get 1 share of $PS (the GP). It sounds like the PSUS offering will be 100mm shares at $50/share or $5 bn. Ackman thought this was going to be a $10 bn offering and he previously was targeting $25 bn or some ridiculous amount. The PSUS IPO investors will end up owning 20mm shares or 5% of PS (based on 400mm pf s/o). I expect that PSUS, like many closed end funds, will settle at a 5-10% discount to NAV, implying a trading price of $45-47.50/share. PS will begin trading as well (via a direct listing) and I anticipate a valuation of $5-10bn, implying that the PSUS IPO investors will get a "bonus" of $250-500mm on the $5 bn IPO or 5-10%. Therefore their loss on the PSUS shares should be mostly offset by the free shares in PS. Given this is a direct listing, I expect WILD price movements in PS stock and would stay far away from that one. I used $10 bn as the high end valuation for PS because that is where investors invested back a year or so ago (predicated upon significant growth in AUM), but I tend to believe that was a high watermark and not realistic given that Ackman can't seem to raise $. In terms of $PSUS, I don't see a compelling reason to own this at 90-95% of NAV. If you put a 15x on the 2% fee, that alone is a 30% drag. Also, Ackman has high volatility and there is no prospect to ever get repaid (and no incentive for Ackman to do so). Like $PSH.LN I would personally only step into $PSUS at a 25-30%+ discount to NAV and probably not in any real size.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

MYRG $4B
Monte Independent Investment Research 4 clicks

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 7 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $110M
Triple S Special Situations Investing 4 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $110M
Value Investors Club

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $16M
Atrium Research - Equity Research 1 click

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Wednesday, October 21 54 stock ideas
  • Why I sold OB pick for 26 SVM The Oak Bloke
  • CoreWeave: It’s Not Dying, Not Anytime Soon Capitalist Letters
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 54 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick